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AD = Alzheimer’s disease, Aβ = amyloid beta, AβO = amyloid beta oligomer, SLF = spin-labeled fluorene, FCS = 
fluorescence correlation spectroscopy, CD = circular dichroism spectroscopy, EPR = electron paramagnetic 
resonance spectroscopy, APP = amyloid precursor protein  
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Abstract 
Alzheimer’s disease is characterized by the presence of extracellular plaques comprised of amyloid beta 
(Aβ) peptides. Soluble oligomers of the Aβ peptide underlie a cascade of neuronal loss and dysfunction 
associated with Alzheimer's disease. Single particle analyses of Aβ oligomers in solution by fluorescence 
correlation spectroscopy (FCS) were used to provide real-time descriptions of how spin-labeled fluorenes 
(SLFs; bi-functional small molecules that block the toxicity of Aβ) prevent and disrupt oligomeric 
assemblies of Aβ in solution.  Furthermore, the circular dichroism (CD) spectrum of untreated A shows 
a continuous, progressive change over a 24-hour period, while the spectrum of A treated with SLF 
remains relatively constant following initial incubation. These findings suggest the conformation of Aβ 
within the oligomer provides a complementary determinant of Aβ toxicity in addition to oligomer growth 
and size.  Although SLF does not produce a dominant state of secondary structure in A, it does induce a 
net reduction in beta secondary content compared to untreated samples of A. The FCS results, combined 
with electron paramagnetic resonance spectroscopy and CD spectroscopy, demonstrate SLFs can inhibit 
the growth of Aβ oligomers and disrupt existing oligomers, while retaining Aβ as a population of smaller, 
yet largely disordered oligomers.   
 
Keywords: amyloid beta, oligomer, spin-labeled fluorene, secondary structure, fluorescence correlation 
spectroscopy, circular dichroism spectroscopy 
 
 
Short title:  Aβ conformation, oligomerization and toxicity. 
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1. Introduction 
 
Alzheimer’s disease (AD) is a progressive, neurodegenerative disease of aging resulting in gradual loss of 
cognitive function.  Although the primary cause of AD is still unknown, the defining histopathological 
features of the disease are well-established.  AD is characterized by the presence of two distinct features: 
insoluble extracellular amyloid beta (Aβ) plaques, and intracellular neurofibrillary tangles resulting from 
aggregates of hyperphosphorylated tau, a microtubule-associated protein.  Aβ plaques are generated from 
the aggregation of soluble Aβ peptides that are formed when γ and β secretases cleave amyloid precursor 
protein (APP), a constitutively expressed transmembrane protein.  These Aβ peptides possess an 
inherently disordered nature, which leaves them prone to progressive aggregation as oligomers, then 
proto-fibrils and fibrils, and finally mature plaques.   
 
While a central role of A in Alzheimer’s disease is well-established, mechanistic studies over the past 
decade have focused on its soluble form, as the presence of amyloid plaques containing fibrillar, insoluble 
forms of A were found to poorly align with the severity of Alzheimer’s disease symptoms.  
Measurements taken in vivo and in cell culture have demonstrated the soluble, oligomeric state of A 
(AβO) results in greater neuronal toxicity and impairment compared to the peptide in its fibrillar assembly 
[1-6]. The physiochemical properties of soluble A are driven by its intrinsic disorder [7], which drives 
dynamic flux in both the oligomeric state and the structure of the assembled peptides.  Since AβO acts as 
a moving target, the examination of this problem is furthered by methods that can capture dynamic states 
of biomolecules in solution [8, 9].     
 
Soluble, non-fibrillar Aβ assemblies have been implicated as the primary cause of synaptic dysfunction 
and cognitive decline in AD. Identification of the particular conformational species responsible for these 
deleterious effects has been challenging due to the enormous heterogeneity of Aβ assemblies. However, a 
growing body of evidence suggests a relationship between toxicity, size, and surface hydrophobicity of 
amyloid aggregates, with maximum toxicity attributed to aggregates with a high surface-to-volume ratio 
[1, 10-14]. Antibodies have been selected to discriminate between conformational states of Aβ, with the 
A11 antibody reactive against neurotoxic oligomers of amyloidogenic species, and the OC 
immunoglobulin recognizing more compact and less toxic assemblies [5]. In vivo studies investigating the 
neurotoxicity of different Aβ species have identified a range of candidates based on oligomer size, 
including low molecular mass (< 10 kDa) Aβ oligomers [6, 15], as well as larger oligomers (> 50 kDa) 
[16] that cause detrimental effects on cognitive ability. 
 
A major impediment to the development of anti-A compounds for AD therapy is that essentially 100% 
of large-molecule drugs and greater than 98% of small-molecule drugs fail to cross the blood brain barrier 
(BBB) [17].  In addition, extracellular and intraneuronal AO seem to exist in a dynamic equilibrium, 
with toxicity arising from both pools [18].  Thus, high cell permeability should also be considered 
necessary for an effective AO antagonist.  We have identified fluorene compounds, based on a highly 
rigid tricyclic fluorene ring originally developed as potential PET and SPECT imaging agents, on the 
basis of their amyloid affinity and blood brain barrier permeability [19], that are able to permeate cells, 
inhibit A aggregation and neutralize the toxicity of soluble AO [20].  More recently, we have 
synthesized bi-functional fluorenes by attaching nitroxides to the fluorene compound (Figure 1) [21].  
We found the protective effect of these spin-labeled fluorenes (SLFs) is superior to the fluorene template 
and derives from the targeted antioxidant activity of the compound's nitroxide moiety [22].  Thus the 
increased potency of the SLF can be ascribed to its ability to address both conformational and oxidative 
stress [23] aspects of AO toxicity. 
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In this work, we apply fluorescence correlation spectroscopy (FCS) to monitor the effect of the SLF 
compound on the size of Aβ assemblies in solution. FCS is a powerful technique for studying dynamic 
biochemical interactions in vitro and in cells [24-26].  In FCS, random diffusion of fluorescent molecules 
into and out of a femtoliter laser excitation volume leads to fluctuations in fluorescence intensity.  
Correlations calculated from recorded fluorescence signals reveal diffusion and binding properties of the 
molecules.  For diffusion of a single species, the timescale at which the correlation function decays to half 
its amplitude gives the diffusion time, D.  Binding to other molecules or structures may be detected as 
changes in diffusion time, which are reflected by a shift in the autocorrelation curve.  With precise 
knowledge of D and laser beam waist, , the diffusion coefficient and hydrodynamic radius can be 
determined. Thus FCS provides a real-time, in-solution approach that is particularly useful in the study of 
protein aggregation processes inherent to neurodegenerative disorders [27-30]. Here, we apply FCS to 
better understand the manner in which SLFs to modulate Aβ toxicity as correlated to its aggregation, 
disaggregation and oligomeric stability, demonstrating the potential of this approach in identifying agents 
suitable for counteracting the molecular pathogenesis of AD.   
 
 
2. Materials and Methods 
 
2.1 Materials 
Hexafluoro-2-propanol (HFIP) was purchased from Sigma-Aldrich (St. Louis, MO).  Dimethyl sulfoxide 
(DMSO) was purchased from Fisher Scientific (Pittsburgh, PA). Atto 647N NHS ester was obtained from 
Fluka Analytical, Sigma-Aldrich (St. Louis, MO).  Aβ(1-40) peptide was purchased from Bachem (catalog 
number H-1194, Torrance, CA). Amyloid-beta peptide (1-40) containing a TOAC spin label at position 
26 (A(26TOAC)) was synthesized as described in [31]. Spin-labeled fluorene HO-4160 (SLF) and its 
diamagnetic derivative HO-4198 (SLF
dm
) were synthesized as described in [21].  The structures of both 
are given in Figure 1. 
 
2.2 Preparation of Amyloid β Peptide Samples 
The Aβ peptide was dissolved in HFIP and incubated at room temperature with gentle rocking for 48-72 
hours.  SpeedVac or evaporation was then used to remove the HFIP, resulting in a monomeric Aβ pellet. 
Immediately before the given experiment, the HFIP-treated pellet was warmed to room temperature and 
dissolved in fresh DMSO to achieve a stock solution of 1 mM Aβ. To generate oligomers, the Aβ solution 
was then diluted into PBS (pH 7.4) buffer to a final concentration of 40 μM.  The 40 μM solution was 
allowed to incubate at room temperature for the indicated times to produce oligomers.  As demonstrated 
previously [20, 22, 31], these oligomeric preparations are A11-positive oligomers [4], with a 40 M 
solution producing particles of ~10 nm at 4-hours by AFM imaging. 
 
2.3 Cell Viability 
Neuronal toxicity was accessed using the Neuro-2a (N2a) cell line [32].  Cells were plated at a density of 
2.5 x 10
5
 cells/well in a 12-well plate in medium containing 50 IU/mL penicillin and 50 μg/mL 
streptomycin.  The medium was composed of a mixture of  50% Dulbecco’s Modified Eagle Medium 
supplemented with 4.5 mg/mL D-glucose, non-essential amino acids, 1 mM  sodium pyruvate, and 10% 
(v /v) heat-inactivated fetal bovine serum, and 50% Opti-Minimal Essential Medium (without phenol 
red) from Gibco/BRL (Carlsbad, CA).   
 
To measure the toxicity of Aβ(1-40) to N2a cells, a 0.1 mg pellet of HFIP-treated Aβ(1-40) was reconstituted 
in 10 μL DMSO.  Oligomeric Aβ was obtained by dilution in PBS pH 7.4 to a final concentration of 1 
mM and incubation for 24 hours.  Aβ was then added with and without SLF to the growth media at final 
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concentrations of 50 μM for Aβ and 4 μM for SLF. Cytotoxicity was determined using counts of viable 
cells based on Trypan blue exclusion. To verify the nontoxic nature of the SLF, cell viability was also 
determined following incubation with SLF alone up to a concentration of 10 μM. Statistical significance 
between groups was determined by one-way ANOVA on ranks using SigmaStat software (Systat 
Software Inc., San Jose, CA), where p < 0.05 was considered significant. 
 
2.4 Labeling of Amyloid β Peptide Samples with Fluorescent Dye 
To direct preferential labeling of the N-terminal amine group of Aβ, a 0.1 mg aliquot of peptide was 
dissolved in 10 μL DMSO and reacted at pH 7.0 with 3 μL Atto 647N NHS ester label (10 mM stock in 
DMSO) and 500 μL phosphate-buffered saline (PBS; 120 mM NaCl, 25 mM phosphate, pH 7.0).  At this 
pH, the only appreciable level of unprotonated amine (capable of reacting with the NHS-ester probe) 
exists at the N-terminal -amine, whereas >99% of the Lys -amines remain protonated at this pH [33]. 
The mixture incubated for 2 hours at room temperature, and the oligomeric species pelleted by 
centrifugation at 100,000 x g.  To remove unreacted Atto probe, the pellet was washed 6 times with fresh 
PBS.  After the final PBS wash was removed, HFIP was added to the labeled peptide and allowed to 
evaporate.  The resulting pellet was stored at -20°C until use.     
 
2.5 FCS Instrumentation 
We conducted our experiments using a time-resolved confocal fluorescence microscope equipped with a 
640 nm pulsed diode laser (PicoQuant, Germany) operating at a repetition rate of 20 MHz.  Immediately 
prior to each measurement, fluorescently-labeled Aβ samples were diluted to a probe (Atto 647N NHS 
ester) concentration of 10 nM in PBS (pH 7.4). The laser was focused to a diffraction-limited spot of 
~350 nm diameter by an Olympus 1.45 NA 100x oil objective to a height of 5 µm above a glass coverslip 
surface.  The average power was 20 μW at the sample.  The fluorescence emission was split by a dichroic 
mirror (600DCXR, Chroma Tech. Corp., Bellows Falls, VT), spectrally filtered with emission bandpass 
filters (HQ680/75 m, Chroma Tech. Corp., Bellows Falls, VT), and detected by two avalanche 
photodiode detectors (SPCM-AQR-14, PerkinElmer, Waltham, MA).  The signals were processed by a 
time-correlated single-photon counting board (PicoHarp300, PicoQuant, Germany), operating in time-
tagged time-resolved (TTTR) mode. The TTTR mode of the data acquisition records the photon arrival 
time from the last excitation pulse (micro-time) with 50-ps relative time resolution, and the photon arrival 
time from the start of the experiment (macro-time) with 100-ns absolute time resolution. Correlations 
were calculated using the SymPhoTime software package (PicoQuant GmbH, Berlin). Data were fitted to 
maximize χ2 using the Levenberg-Marquardt least-squares method. 
 
2.6 Surface-Bound Species Removal Algorithm 
A common problem in taking accurate FCS measurements is the presence of large intensity spikes. These 
spikes can be due to formation of large aggregates, or the tendency of molecules to stick to glass surfaces, 
as commonly occurs in measurements involving Aβ. These large fluorescent bursts, if not corrected for, 
can skew the results of the analysis, resulting in an autocorrelation curve that is mostly dominated by that 
particular diffusion event. Removal of these intensity spikes is necessary for accurate FCS measurements. 
To eliminate these surface-bound species from our data, we implemented a custom algorithm that cuts a 
portion of the intensity time trace that contains photon bursts greater than 10x the average signal. The 
remaining portion of the time trace is then stitched back into the original time trace for correlation 
analysis.  A detailed description of excluding signal from adhered species is given in [34].    
 
2.7 Circular Dichroism Spectroscopy   
Circular dichroism spectroscopy (CD) measurements were performed on a Jasco J-715 spectropolarimeter 
equipped with a Peltier temperature control (Quantum Northwest) set to 25°C. Since DMSO absorbs 
strongly in the far UV and overlaps with protein absorption spectra, acetonitrile, a UV transparent solvent, 
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was used to reconstitute the A. Dried pellets of HFIP-treated A (0.2 mg) were dissolved in 7 L 
acetonitrile, and 3.5 L of the peptide was added to 300 L of PBS (pH 7.4) plus 3 L of acetonitrile 
(with or without SLF) and allowed to incubate for the indicated times. CD spectra of both samples were 
measured at 0 hours under identical parameters. Care was taken to utilize the same minimal amount of 
acetonitrile in control and +SLF conditions, as the fraction of disordered structure in A is affected by 
solvent [35-37].  In order to minimize the strong far-UV absorption by Cl
-
, NaF was used in place of 
NaCl for PBS solutions in all CD measurements.  For samples analyzed after amorphous aggregate 
removal, 0.32 mg/mL of A peptide was combined with either SLF or acetonitrile vehicle for 15 minutes 
and then centrifuged at 15,000 x g for 5 minutes.  Aβ concentrations in the supernatants were determined 
using a NanoDrop reader with the extinction coefficient estimated from the peptide sequence.  After 
centrifugation, the A concentrations were 0.04 mg/ML and 0.14 mg/mL for the control and +SLF 
samples, respectively.  CD spectra of the supernatants were then measured at the same time intervals and 
using the same parameters. 
 
For spectral acquisition, samples were placed in a 1 mm quartz cuvette and CD spectra were collected by 
signal averaging three scans in the region 190 to 260 nm using a scan speed of 20 nm/min, bandwith of 1 
nm and response time of 4 sec.  Prior to analysis, all spectra were baseline-subtracted from the 
appropriate background buffer containing either the SLF alone or the solvent vehicle (the background 
signals were generally indistinguishable.   The percent of secondary structure was estimated by 
deconvolution using the BeStSel CD analysis program[38], which can be accessed on line at 
http://bestsel.elte.hu. 
 
2.8 Electron Paramagnetic Resonance Spectroscopy 
 
EPR measurements were carried out on preparations of A containing a TOAC spin-labeled amino acid 
substituted at position 26 of the A(1-40) peptide (A
26TOAC)
).  Spin-coupling among proximal TOAC 
labels was attenuated by dissolving HFIP-treated peptide in DMSO and combining 1 part A(26TOAC)  with 
3 parts wild-type A(1-40) to generate a spin-diluted DMSO stock of peptide.  Oligomeric samples for EPR 
were then prepared by dilution of the DMSO stock solution into cold PBS buffer (pH 7.4) for a total A 
peptide concentration of 80 M (containing 20 μM paramagnetic A(26TOAC)). All EPR measurements 
were performed using a JEOL FA-100 X-band spectrometer fitted with a loop-gap resonator. 
Approximately 4 μL of each sample was loaded into a sealed borosilicate glass capillary tube (Fiber Optic 
Center, Inc., New Bedford, MA). The spectra were obtained by averaging three 2-minute scans with a 
sweep width of 100 G at a microwave power of 3 mW recorded at room temperature. The modulation 
amplitude was optimized according to the natural line width of the TOAC spin probe. Spectra were 
processed using Origin 7 software (OriginLab Corporation, Northampton, MA). 
 
3. Results 
 
3.1 SLF blocks the toxicity of Aadded to N2a cells. 
We previously used a neuronal cell culture model capable of inducible over-expression of APP to show 
SLF protects against the toxicity of intraneuronal A [22].  To confirm that SLF converts A to a less 
toxic species, we added SLF to oligomeric A (AO) and added the mixture exogenously to cultured N2a 
neurons.  As shown in Figure 2, no viable cells remained three days after AβO addition.  However, by 
adding SLF to the AO sample prior to its application to the N2a cells, the health and viability of the cells 
after three days resembles that of the control cells.  
 
3.2 SLF inhibits Aβ oligomer growth in solution as monitored by FCS. 
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A primary feature of the A peptide is its propensity to aggregate over time in aqueous solution.  Most 
studies on this process have focused on the stages apparent in amyloid fibril formation, which involves 
the adoption of highly ordered cross-beta structure that typically occurs over a 2-4 week incubation in 
vitro.  In order to monitor the A assembly state associated with higher cellular toxicity, we used FCS to 
measure the diffusion time of A in solution over the first 4 hours of incubation in the presence and 
absence of SLF.  We used a sample solution consisting of 40 μM Aβ labeled with Atto 647 dye.  For each 
FCS measurement, a small volume of this sample was diluted to less than 1 nM in phosphate-buffered 
saline (PBS) to ensure that the excitation volume contains an average of one molecule or less, which gives 
a high signal-to-noise ratio for these conditions while still allowing single molecule burst analysis on 
surface-bound species. We take the FCS measurement immediately after dilution, within one minute or 
less, to minimize the dead-time.  Although simple binary association of SLF can dissociate during this 
period, aggregates do not, as their dissociation would show up as a shift towards a rapid diffusion time on 
the autocorrelation curve. This is not observed in our analysis. The data were recorded for two minutes at 
each time interval.  
 
At the start of the experiment (time zero), monomeric Aβ is the predominant species, with a fast diffusion 
time of 40 μs (Figure 3, black curve; Figure 4).  Significant aggregation occurs within the first 4 hours as 
indicated by the large shift to a slow diffusion time of 7.1 ms (Figure 3, light gray curve; Figure 4). After 
4 hours, a much slower phase of aggregation is observed, with a 24-hour incubation producing a diffusion 
time of 9.3 ms (Figure 4).  In contrast, when a solution of 40 μM Aβ was mixed with 40 μM SLF 
compound, the diffusion time was much faster (Figure 3, red curve).   
 
Fits of the correlation decays provide diffusion rates (D), with optimization indicative of single- or multi-
component samples. Samples treated with SLF fit best with a two-component model consisting of a fast 
species with a correlation time of  ≤ 0.1 ms and a slower species on the order of 4-7 ms (Figure 4; Table 
S1).  The exception is AO aggregated over 24 hours, which lacks a significant contribution from the 
faster component until it has been in the presence of SLF for 4 hours (Figure 4; Table S1).  For all 
samples displaying two components, the slower component predominates, representing 60-85% of the 
species (Table S1). At 4 hours, the sample with SLF fits best with a two-component diffusion species 
model, where 15% of the total fraction is from 1 = 85 μs and 85% is from 2 = 4.5 ms. The emergence of 
two diffusion times is likely due to the interaction with SLF that breaks the complex into particles with a 
wider distribution of  sizes. 1 represents smaller (on the order of a monomer or dimer) Aβ particles while 
the majority of the peptide remains oligomeric. The χ2 of these fits were between 1.1 and 1.5.   
 
3.3 SLF disrupts larger oligomers of A. 
We also monitored the effect of SLF on a solution containing oligomerized Aβ to test the ability of the 
molecule to disrupt pre-formed Aβ aggregates. First we looked at the effect of adding SLF to a 4-hour 
AβO incubation (Figure 5, red curve).  The diffusion time for this sample is 4.2 ms, a substantial 
decrease from  τ = 7.1 ms prior to SLF addition (Figure 4). This indicates the SLF converts AO into 
smaller (more rapidly diffusing) species. The rate of diffusion for the 4-hour AβO sample treated with 
SLF is on the order of samples containing SLF from the onset of peptide incubation in buffer (i.e., 4-5 
ms).  However, when the same experiment is carried out on 24-hour AO, the diffusion correlation time 
only decreases to 6.6 ms (Figure 4; Figure 5, blue curve).    
 
3.4 Photon burst analysis supports FCS analysis showing disruption of oligomerization. 
We performed burst analysis to analyze the intensity and width of each fluorescence burst corresponding 
to individual large oligomers.  Larger oligomers lead to photon bursts with higher intensities and longer 
widths.  A time trace for a 2-minute diffusion event is shown for Aβ alone and Aβ + SLF incubated 
together for 4 hours (Figure 6A).  In the absence of SLF, Aβ displayed wider and more intense bursts due 
to the formation of large oligomers (black trace).  In the presence of SLF, the intensity of these 
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fluorescent bursts decreased (red trace).  Burst histograms were generated to show the number of events 
with a specific photon count (Figure 6B).  The burst histogram is derived from the intensity time trace at 
4 hours and counts all the photons within the burst regardless of the length of the burst.  For free Aβ, there 
were many bursts containing over 500 counts, with some bursts approaching over 1000 counts due to 
rapid aggregation of Aβ.  The mean time of each burst was 2.1 ms (Figure 6C) with some bursts 
extending beyond 50 ms. In contrast, the Aβ-SLF complex contained mostly smaller particles, thus the 
majority of bursts were less than 200 counts/ms with average burst width of 1.7 ms.  In our analysis of all 
samples, extremely large bursts over 1000 counts/ms (Figure 6D) that are not a true representation of the 
species are removed with the surface-bound species removal algorithm.  To summarize, Aβ alone resulted 
in large intensity bursts with large burst times, while the Aβ-SLF complex resulted in smaller burst 
intensity and shorter burst time.  These observations, coupled with FCS measurements, demonstrate the 
ability of the SLF molecule to inhibit Aβ oligomerization.  
 
3.5 SLF decreases the fraction of beta strand structure in oligomeric A. 
In order to determine whether the complex oligomerization of A observed by FCS reveals corresponding 
secondary structure changes, we measured the circular dichroism (CD) spectra of A over a 24-hour time 
period. The spectral changes in oligomeric A over 24 hours are complex (Figure 7A).  The secondary 
structural values resulting from deconvolution are given in Table S2 and plotted in Figures 7C and 7D. 
The analysis of secondary structure contribution for untreated peptide reveals an increase in peptide 
disorder over the first 4 hours, and then a drop in the fraction of unstructured peptide at 24 hours (Figure 
4C).   
 
The effect of SLF on the time-dependent changes in Aβ secondary structure is shown in Figure 7B, with 
the deconvolution of secondary structure components plotted in Figure 7D.  A notable difference 
compared to the spectra of the control sample is that the +SLF spectra display similarity for the 2- to 24-
hour time points, with only modest changes occurring in the far-UV range.  Regarding secondary 
structure content, the most obvious difference over all time points relative to control lies in the amplitudes 
of the unstructured components (lower in SLF) and the alpha components (higher in SLF). As shown in 
Figure 7D, SLF results in a substantial decrease in unstructured peptide over the first 4 hours, 
corresponding with a population converted into helical structure.  However with time, the +SLF sample 
displays a rise in unstructured amplitude, which is mirrored by a decrease in alpha-helical content over 24 
hours.  In contrast, the beta and turn components are relatively unchanged over this same period.  As 
discussed below, the lack of increase in beta structure for the +SLF sample at 24 hours is of significance, 
since the size of the oligomeric species determined by FCS is best correlated with its amount of beta 
structure determined by CD. This is also consistent with the nature of the 4-hour A sample in the 
absence of SLF, which displays both the fastest correlation time and the lowest fraction of beta content. 
 
Previous CD analysis has demonstrated that the large amorphous aggregates formed by A in aqueous 
solution generate a skewed CD spectrum, due to the ability of such species to absorb UV light, but not 
behave as CD-active chromophores [39, 40].  We therefore repeated CD analysis on A sample cleared of 
such aggregates by centrifugation (see Methods).  This procedure is particularly informative in that it 
provides another demonstration that SLF inhibits the formation of such aggregates, as ~3.5x more A 
remains in the supernatant if SLF is present. As shown in Figure 8, removal of the amorphous aggregates 
affects both the control and +SLF CD spectra, although the effect is far more profound in the control 
sample, consistent with the SLF compound reducing the amount of large aggregates.  With respect to the 
fractions of calculated secondary structure, the results are largely similar in that the primary difference 
between control and SLF-treated A remains a lowered amount of beta structure in the latter. 
  
3.6 SLF addition to 24-hour mature AO produces a unique CD spectrum, with a decrease in the 
spectral intensity at the beta-I region compared to 24-hour A lacking SLF treatment. 
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As the FCS findings in Figure 3 show the ability of SLF to disrupt oligomers after 4 hours of treatment, 
as well as prevent their growth, we then looked at the secondary structure of the disrupted 24-hour 
oligomer.  Fresh A was incubated in PBS for 24 hours, treated with 40 M SLF, incubated for another 4 
hours, and then analyzed by CD spectroscopy.  As shown in Figure 9, the CD spectrum of this sample is 
distinct from sample containing SLF from the onset of incubation.  The secondary structure values 
resulting from deconvolution are shown in Table S2. Compared to the 24-hour sample with SLF present 
from the onset, the major effect of SLF addition to 24-hour A is a decrease in the amount of unstructured 
A.  This is consistent with a mechanism where more structured forms of A dissociate from oligomers 
in the presence of SLF. 
 
3.7 Disassembly of 24-hour mature AO is also evident by EPR.Electron paramagnetic resonance 
(EPR) spectroscopy of spin labels attached to A has been used to resolve the arrangement of the peptide 
in fibrils [41] and oligomers [42, 43]. We have previously used the dynamics of a TOAC-incorporated 
spin label (A(26TOAC)) to show the SLF compound inhibits the time-dependent ordering of the Apeptide 
in aqueous solution [22].  In these measurements, spin-labeled A is mixed with unlabeled A (25% mole 
fraction of A(26TOAC)) to attenuate the spectral broadening arising from dipolar magnetic interaction 
among nearby spins in the oligomer.  The EPR spectrum of A(26TOAC) freshly added to PBS is shown in 
Figure 10A (black trace).  To ascertain the ability of SLF to disrupt AO of increasing maturity, we 
added the diamagnetic version of SLF (SLF
dm
) so that only the A(26TOAC) signal is observed by EPR. At 
the initial time point, addition of SLF
dm
 results in a slight broadening of the EPR spectrum, most likely 
due to the restriction of local dynamics induced by SLF
dm
 binding Figure 10A (red trace).  After 24 hours 
in PBS, the spectum of A(26TOAC) reveals considerable broadening, due largely to the slower correlation 
time of the larger aggregate (Figure 10B, black trace).  However, addition of a stoichiometric amount of 
SLF
dm
 to the 24-hour sample alleviates much of this broadening (Figure 10B, red trace), consistent with a 
faster correlation time for A(26TOAC) after SLFdm treatment.  These results support FCS results showing 
SLF
dm
 disrupts 24-hour oligomers of A.   
 
3.8 Tightly packed AO generated by Zn(II) are largely resistant to SLF disruption. 
To further probe the efficacy of SLF to disrupt AO, we used Zn(II) to generate large, non-fibrillar 
aggregates of A[44-46].  In addition to increasing the rate and size of A aggregation, micromolar 
Zn(II) produces a highly stable form of aggregate that demonstrates resistance to protease treatment [47].  
Because Zn(II) levels can be substantial (up to 60 M) at the neuronal synapse, its profound physical 
effect on A has been postulated to increase [46] and decrease [44, 48] the toxicity of A (reviewed in 
[49]).  As shown in Figure 11A, addition of stoichiometric (80 M) Zn(II) to A immediately results in a 
severely broadened EPR spectrum.  Although the sample contains only 25% A(26TOAC), dipolar 
interaction undoubtly contributes to the spectrum given the extent of broadening.  This suggets a very 
close packing of  Zn(II)-coordinated peptides.  This effect becomes slightly more pronounced over 24 
hours (Figure 11A).  We then tested whether SLF
dm
 can disrupt Zn(II)-treated A that has incubated for 4 
hours. In contrast to the Zn(II)-free AO sample (Figure 11B), addition of SLFdm provides only marginal 
relief of the spectral broadening (Figure 10B, green trace).  Finally, we also investigated whether 
including SLF
dm
 prior to Zn(II) addition is capable of blocking the metal-induced aggregation. As shown 
in Figure 11B (blue trace), A pretreated with SLFdm  displays less spectral broadening than the Zn(II)-
A sample lacking SLF (Figure 11B, red trace), however the relief in broadening is on the order of what 
is observed when SLF
dm 
 is added after a 4-hour incubation with Zn(II).  Thus, while SLF
dm 
 is capable of 
disrupting or blocking the growth of A oligomers, at stoichiometric levels it shows marginal activity in 
the presence of Zn(II).   
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4. Discussion 
  
The etiology of multiple neurodegenerative diseases stems from proteins or protein fragments containing 
poorly defined structural regions that aggregate and coalesce into insoluble deposits [50].  Efforts to 
elucidate the molecular pathology of such disorders are complicated not only by the heterogeneity of the 
toxic species, but also by the ability of these species to disrupt a range of cellular processes. For example, 
AO appears to have multiple cellular targets [51], inducing not only neuronal apoptosis, but also 
neuronal functions such as outgrowth and synaptic signaling. Additionally, A has been shown to impair 
glial cell function, including that of both astrocytes [52] and microglia [53]. Thus toxicity must be used in 
a broad sense for A and other agents that propagate through intrinsic disorder and aggregation. The 
connection between structure and assembly is central to this problem, as aggregation affects secondary 
structure and secondary structure affects aggregation rates [7, 50].  Thus while several studies have 
correlated toxicity with a specific oligomeric state (e.g., [6, 16]), it is equally important to ascertain the 
structure (or lack thereof) and dynamics of A in these assemblies.   
 
The conversion of more recent in situ studies supports a more complex toxicity mechanism involving an 
"oligomeric soup" of A species undergoing a dynamic equilibrium dominated by species heterogeneous 
in both size and secondary structure [54].  Early investigations of Aβ aggregation kinetics and structure 
exhibited variable conclusions regarding aggregate size/structure and the kinetics of aggregation [55-58]. 
As such, even slight differences in conditions and temporal variation can complicate comparative 
analyses. The lack of structural specificity is consistent with A disrupting and dis-regulating multiple 
cellular processes, and the multi-factorial nature of AD in general.  This complicates the design of 
biophysical studies as well, which can been simplified by manipulating solvent conditions and removing 
large amorphous aggregates by centrifugation prior to analysis [39, 40, 59, 60].   Although our 
experiments are challenged by the heterogenous nature of oligomeric A, it is important to access the 
influence of structural modulators in the context of this dynamic equilibrium. While SLF limits both the 
progression of aggregation and the extent of secondary structural change over time, it does not convert 
A into a well-defined oligomeric or structural state. Thus analyses using other biophysical tools capable 
of observing A under equilibrium conditions, such as DLS [61, 62], are warranted.   
 
CD spectra of A are highly dependent on the experimental conditions, including the peptide 
concentration and version (1-40 or 1-42), solution temperature, ionic strength, and pH. Our measurements 
of early A species in PBS buffer contain spectral features resembling II-class proteins, structures that 
are high in short, distorted beta strands and combined with a high degree of unordered backbone [63].  
This contrasts with the CD spectra from I proteins, where adjacent strands are closely paired in H-
bonding and generate a broad negative band centered around ~215 nm and a positive band at 197 nm 
[63].  Dominant pleated beta structure in A(1-40) is typically achieved in vitro after 24 or more hours, 
during its slow maturation into protofibrils and adoption of a I-type CD spectrum, which becomes more 
characteristic after several days [64].  Additionally, after clearance of large amorphous aggregates A 
treated with SLF displays CD features resembling the poly(Pro)II-type helix (i.e., a relatively sharp 
negative band at ~197 and a positive band in the >210 nm region).  This CD pattern is not uncommon in 
unstructured peptides [65], and can be increased in A at lower temperatures [66].  Since this signal was 
identified with residues in the N-terminal portion of A [66], future studies can explore whether SLF has 
a larger conformational effect on this region of the peptide.   
 
Our previous measurements showed SLF reduces ThT staining, the appearance of 10 nm particles in 
AFM, and spin magnetic coupling among spin labels incorporated into A [22].  Thus we considered the 
possibility that SLF may act by blocking oligomer formation. However, while SLF clearly inhibits 
oligomer growth and decreases oligomer size, our FCS findings of oligomeric A in the presence of SLF 
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demonstrate a form of AO with little-to-no toxicity. These results are in line with a study of 
tetracycline's effect on A toxicity and oligomerization, where tetracycline was found to produce a stable 
distribution of soluble oligomers with low toxicity to cultured neurons [67].  FCS measurements also 
allow us to distinguish the SLF response of early oligomers (4 hours or less) from more mature oligomers 
(24 hours). Within the first 4 hours of oligomer formation, regardless of whether the SLF is added before 
or after peptide assembly, a similar (~ 4 ms) diffusion time is observed.  Whereas following a 24-hour 
aggregation period, SLF does reduce diffusion times, but only to 6.6 ms. This is consistent with the 
distinct CD spectra of 24-hour A in the presence of SLF, differentiated by whether the sample contains 
SLF from the onset of its incubation or the SLF is added at 24 hours.   
 
Based on the FCS measurements, our treatment of cultured neurons with A-SLF involved two 
oligomeric species of A: ~70% having a molecular diameter on the order of 4-5 nm, and the remainder 
residing as a monomer or dimer.  The fact that no effect on cell viability is observed with this mixture 
indicates a loss of toxicity for the SLF-A mixture in either oligomeric state. The attenuation of AO 
toxicity by SLF provides insight into the conformational elements within AO that can be associated with 
cellular toxicity.  Previous studies have identified the level of beta structure in AO with increased 
toxicity [1, 36, 42, 66, 68, 69], including observations that the "arctic" mutations in A increase beta 
structure within the oligomer [69, 70]. Notably, Cohen et al have proposed that the seeding of beta 
structure in soluble A by fibril ends may represent a key molecular mechanism in AD pathology [68]. 
Our CD measurements are in agreement with this notion, in that SLF decreases beta structure in A by 
~10%, and can reduce the beta content within 24-hour mature AO.  
 
The ability to inhibit peptide aggregation and fibrilization has been found with other small molecules that 
show protective activities against A toxicity [36, 71-73].  In the case of tetracycline, soluble A is not 
dispersed into monomers, but maintains a supramolecular complex that remains soluble and stable over 
time [71]. This observation is particularly interesting, as the same study showed the peptide in complex 
with tetracycline retains very little beta sheet content, remaining in a disordered state. This observation, in 
addition to our finding that the most consistent effect of SLF on A structure is its ability to hinder an 
increase in beta secondary structure, suggests oligomer size alone may not serve as a useful predictor of 
Atoxicity. Rather, the growth capability and/or the secondary structure within the oligomer are likely to 
be more informative metrics with respect to peptide toxicity. 
 
As studies indicate the neurodegenerative effects of AD derive largely from the toxicity of soluble A 
oligomers [1-6, 68], rational therapeutic interventions must focus on ameliorating the detrimental effects 
of these species. Our results demonstrate a novel class of bi-functional nitroxide-containing fluorene 
compounds, spin-labeled fluorenes or SLFs, have the ability to interfere with the oligomerization process 
and disrupt mature oligomers to produce less toxic species. We used fluorescence correlation 
spectroscopy to monitor the dynamic biochemical interactions between A oligomers and SLFs in 
solution. Fluorescence correlation, electron paramagnetic resonance, and circular dichroism spectroscopic 
methods uniformly indicate SLFs slow the formation of A oligomers and maintain A as smaller 
species, disassemble mature oligomers, and lower the fraction of beta secondary structure in the largely 
dissordered oligomers. SLFs provide ideal candidates for AD therapeutics given their affinity for A 
peptides and permeability to cells and the blood-brain barrier [19-22]. By further elucidating the 
interactions between SLFs and Aβ assemblies, our work provides insight into the potential of these 
compounds as anti-Aβ agents to help slow or prevent the progression of AD.   
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Figure Legends 
 
Figure 1.  Structures of the paramagnetic (top) and diamagnetic (bottom) SLF compounds used in this 
study. 
 
Figure 2.  SLF protects N2a cells against exogenous A.  Shown are images of N2a cells after three 
days with treatment of either DMSO vehicle control (A) or addition of exogenous AO (A incubated for 
24 hours in PBS to generate oligomers prior to addition to the culture media at a final concentration of 50 
M; B). A toxicity is readily apparent from both the decreased cell count and the poor morphology of 
cells in panel B. When Ais combined with 4 M SLF prior to culture application (panel C), cell 
viability resembles the control in panel A.  N2a cell viability was quantified using Trypan blue exclusion 
(panel D). SLF alone was tested at 10 M. Results are expressed as means ± SD of percent cells alive 
following treatment. * p < 0.05 compared to media treatment. 
 
Figure 3.  FCS measurements of 40 μM Aβ in the absence and presence of 40 μM SLF.  The 
diffusion time at the start of the measurement is 40 μs due to the presence of monomeric or dimeric forms 
of Aβ (black curve).  For free Aβ, self-aggregation causes the FCS curve to shift to a very slow diffusion 
time (gray solid arrow) of over 7 ms at the 4-hour mark.  In the presence of SLF, the FCS curve shows a 
much faster diffusion time.  With the addition of SLF, the FCS curve fits best with a two-component 
diffusion species model, where 15% of the total fraction is from τ1 = 85 μs and 85% is from τ2 = 4.5 ms.  
τ1 is from small Aβ particles while τ2 is mostly dominated by Aβ+SLF complexes.   
Figure 4.  Diffusion times calculated from decays of FCS autocorrelation of Atto 647-labeled A 
samples.  Diffusion results are fit with 
1
single-component and 
2
two-component models. For the two-
component fits, only the longer (τ2) correlation time is shown. In the two-component case, τ1 represents 
15-30% of the population and is on the order of 0.1 ms  (see Table S1).  
Figure 5. Effect of SLF on the FCS decay of Aβ.  Shown are FCS measurements of A (40 μM) 
following a 4-hour (light gray curve) or 24-hour (dark gray curve) incubation in PBS.  Disruption of pre-
formed AβO was probed by measuring the FCS of the 4-hour (red curve) or 24-hour (blue curve) sample 
following SLF treatment (40 μM), and incubating for an additional 4 hours.   
Figure 6.  Photon burst analysis of A and A+SLF.  (A)  Fluorescence time trace of A (40 μM) in 
the absence (black) and presence (red) of SLF (40 μM) at 4 hours.  Frequency of events as a function of 
(B) burst intensity and (C) burst time, and fit with a single exponential decay model. In the absence of 
SLF, the A bursts are more intense and longer in time compared with the addition of SLF.  This 
demonstrates the presence of SLF inhibits oligomer growth.  (D) Extremely large fluorescent bursts over 
1000 counts/ms that are removed with the surface-bound species removal algorithm.    
Figure 7. Time-dependent changes in the secondary structure of oligomeric A.  Shown are the 
circular dichroism (CD) spectra of A (in PBS, pH 7.4) in the absence (A) and presence (B) of a 
stoichiometric amount of SLF.  The fractions of calculated secondary structure within the peptide are 
shown in panels C (no SLF present) and D (40 M SLF present).  Scans were carried out on 0.1 mg/mL 
A as described in the Methods.   The BeStSel program was used for the deconvolution of secondary 
structure. 
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Figure 8. CD analysis of A after removal of large amorphous aggregates.  Shown are the circular 
dichroism (CD) spectra of A sample supernatants (in PBS, pH 7.4) in the absence (A) and presence (B) 
of a stoichiometric amount of SLF following centrifugation at 15,000 x g for 5 minutes.  The fractions of 
calculated secondary structure within the peptide are shown in panels C (no SLF present) and D (40 M 
SLF present).  The BeStSel program was used for the deconvolution of secondary structure. 
Figure 9. Effect of SLF on the secondary structure of 24-hour oligomers. CD spectrum of A in PBS 
after 24 hours (black trace) is compared with the same sample containing addition of a stoichiometric 
amount of SLF at 24 hours (spectrum collected following an additional 4-hour incubation period; red 
curve). For comparison, the 24-hour A sample containing SLF from the onset (from Figure 7) is also 
shown (blue trace). 
Figure 10. EPR analysis of A(26TOAC) shows disruption of mature AO by SLF.  SLFdm addition (80 
M) to a fresh preparation of A in PBS buffer induces a slight broadening of the EPR line shape (A).  
Incubation of A for 24 hours results in a broadened spectrum (B, black trace).  SLFdm addition (80 M) 
relieves the spectral broadening (B, red trace), generating a signal similar to the red trace in panel (A). 
Total A in each sample is 80 M.  To attenuate dipolar broadening, only 25% of the peptide is 
A(26TOAC), with native A(1-40) comprising the remaining fraction. Scans were taken over 100 G with all 
spectra scaled to the same number of spins. 
Figure 11. SLF shows a limited ability to disrupt Zinc-fortified aggregates of A.  The EPR spectrum 
of A(26TOAC) in PBS containing 80 M Zn(II) as a function of incubation time is shown in (A).  In panel 
B, SLF
dm
 (80 M) was added to the 4-hour Zn(II)-A sample, incubated for 1 hour, and then scanned by 
EPR (green trace).  The result is a slight reduction in broadening compared to the untreated Zn(II) sample 
at 4 hours (B, red trace).  A similar result is found when SLF
dm
 is added prior to Zn(II) addition and the 
whole mixture incubated for 4 hours (B, blue trace).  The 4-hour A sample without Zn(II) is shown for 
comparison (B, black trace).  Total A in each sample is 80 M.  To attenuate dipolar broadening, only 
25% of the peptide is A(26TOAC), with native A(1-40) comprising the remaining fraction. Scans were taken 
over 100 G with all spectra scaled to the same number of spins. 
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Highlights 
• The small molecule SLF blocks Aβ toxicity, inhibits oligomer growth and disrupts larger oligomers. 
• SLF arrests Aβ in a distribution of smaller oligomers and decreases the amount of beta strand content, 
although the species remain largely disordered. 
• After 24-hours in the presence of SLF Aβ oligomers are about half the size of control sample and 
contain ~10% less beta structure compared to untreated Aβ. 
• The ability of FCS to sample single molecules and assemblies in solution provides a sensitive and 
quantitative method to evaluate modulators of Aβ oligomerization. 
